Age and sex associate with outcome in older AML and high risk MDS patients treated with 10-day decitabine

Author:

Hilberink Jacobien R.ORCID,van Zeventer Isabelle A.,Chitu Dana A.,Pabst ThomasORCID,Klein Saskia K.ORCID,Stussi GeorgORCID,Griskevicius Laimonas,Valk Peter J. M.ORCID,Cloos Jacqueline,van de Loosdrecht Arjan A.,Breems Dimitri,van Lammeren-Venema Danielle,Boersma Rinske,Jongen-Lavrencic Mojca,Fehr Martin,Hoogendoorn Mels,Manz Markus G.ORCID,Söhne Maaike,van Marwijk Kooy Rien,Deeren Dries,van der Poel Marjolein W. M.,Legdeur Marie Cecile,Tick Lidwine,Chalandon Yves,Ammatuna Emanuele,Blum SabineORCID,Löwenberg BobORCID,Ossenkoppele Gert J.,Chitu D. A.,Klein S. K.,Griskevicius L.,Valk P. J. M.,Cloos J.,van de Loosdrecht A. A.,Breems D.,van Lammeren-Venema D.,Boersma R.,Jongen-Lavrencic M.,Söhne M.,van Marwijk Kooy R.,Deeren D.,van der Poel M. W. M.,Legdeur M. C.,Tick L.,Ammatuna E.,Löwenberg B.,Ossenkoppele G. J.,Huls G.,Pabst T.,Stussi G.,Fehr M.,Manz M. G.,Chalandon Y.,Blum S.,Huls Gerwin, ,

Abstract

AbstractTreatment choice according to the individual conditions remains challenging, particularly in older patients with acute myeloid leukemia (AML) and high risk myelodysplastic syndrome (MDS). The impact of performance status, comorbidities, and physical functioning on survival is not well defined for patients treated with hypomethylating agents. Here we describe the impact of performance status (14% ECOG performance status 2), comorbidity (40% HCT-comorbidity index ≥ 2), and physical functioning (41% short physical performance battery < 9 and 17% ADL index < 6) on overall survival (OS) in 115 older patients (age ≥ 66 years) treated on a clinical trial with a 10-day decitabine schedule. None of the patient-related variables showed a significant association with OS. Multivariable analysis revealed that age > 76 years was significantly associated with reduced OS (HR 1.58; p = 0.043) and female sex was associated with superior OS (HR 0.62; p = 0.06). We further compared the genetic profiles of these subgroups. This revealed comparable mutational profiles in patients younger and older than 76 years, but, interestingly, revealed significantly more prevalent mutated ASXL1, STAG2, and U2AF1 in male compared to female patients. In this cohort of older patients treated with decitabine age and sex, but not comorbidities, physical functioning or cytogenetic risk were associated with overall survival.

Publisher

Springer Science and Business Media LLC

Subject

Oncology,Hematology

Cited by 3 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3